198 related articles for article (PubMed ID: 36316084)
1. Phase III, randomised, double-blind, placebo-controlled, multicentre trial to evaluate the efficacy and safety of rhGAD65 to preserve endogenous beta cell function in adolescents and adults with recently diagnosed type 1 diabetes, carrying the genetic HLA DR3-DQ2 haplotype: the DIAGNODE-3 study protocol.
Ludvigsson J; Eriksson L; Nowak C; Teixeira PF; Widman M; Lindqvist A; Casas R; Lind M; Hannelius U
BMJ Open; 2022 Oct; 12(10):e061776. PubMed ID: 36316084
[TBL] [Abstract][Full Text] [Related]
2. Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2.
Nowak C; Lind M; Sumnik Z; Pelikanova T; Nattero-Chavez L; Lundberg E; Rica I; Martínez-Brocca MA; Ruiz de Adana M; Wahlberg J; Hanas R; Hernandez C; Clemente-León M; Gómez-Gila A; Ferrer Lozano M; Sas T; Pruhova S; Dietrich F; Puente-Marin S; Hannelius U; Casas R; Ludvigsson J
J Clin Endocrinol Metab; 2022 Aug; 107(9):2644-2651. PubMed ID: 35665810
[TBL] [Abstract][Full Text] [Related]
3. Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial.
Ludvigsson J; Sumnik Z; Pelikanova T; Nattero Chavez L; Lundberg E; Rica I; Martínez-Brocca MA; Ruiz de Adana M; Wahlberg J; Katsarou A; Hanas R; Hernandez C; Clemente León M; Gómez-Gila A; Lind M; Lozano MF; Sas T; Samuelsson U; Pruhova S; Dietrich F; Puente Marin S; Nordlund A; Hannelius U; Casas R
Diabetes Care; 2021 Jul; 44(7):1604-1612. PubMed ID: 34021020
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes.
Hannelius U; Beam CA; Ludvigsson J
Diabetologia; 2020 Oct; 63(10):2177-2181. PubMed ID: 32754804
[TBL] [Abstract][Full Text] [Related]
5. Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol.
Gregory JW; Carter K; Cheung WY; Holland G; Bowen-Morris J; Luzio S; Dunseath G; Tree T; Yang JHM; Marwaha A; Ali MA; Bashir N; Hutchings HA; Fegan GW; Stenson R; Hiles S; Marques-Jones S; Brown A; Tatovic D; Dayan C
BMJ Open; 2021 Oct; 11(10):e049595. PubMed ID: 34663658
[TBL] [Abstract][Full Text] [Related]
6. Assessing the effect of closed-loop insulin delivery from onset of type 1 diabetes in youth on residual beta-cell function compared to standard insulin therapy (CLOuD study): a randomised parallel study protocol.
Boughton C; Allen JM; Tauschmann M; Hartnell S; Wilinska ME; Musolino G; Acerini CL; Dunger PD; Campbell F; Ghatak A; Randell T; Besser R; Trevelyan N; Elleri D; Northam E; Hood K; Scott E; Lawton J; Roze S; Sibayan J; Kollman C; Cohen N; Todd J; Hovorka R;
BMJ Open; 2020 Mar; 10(3):e033500. PubMed ID: 32169925
[TBL] [Abstract][Full Text] [Related]
7. Prolonged Remission Induced by FENofibrate in children with newly diagnosed type 1 diabetes (PRIFEN): protocol of a randomised controlled trial.
Groele L; Dżygało K; Kowalska A; Szypowska A
BMJ Open; 2024 Feb; 14(2):e076882. PubMed ID: 38341215
[TBL] [Abstract][Full Text] [Related]
8. Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype.
Puente-Marin S; Dietrich F; Achenbach P; Barcenilla H; Ludvigsson J; Casas R
Front Immunol; 2023; 14():1112570. PubMed ID: 36817467
[TBL] [Abstract][Full Text] [Related]
9. Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial.
Johansen NJ; Dejgaard TF; Lund A; Vilsbøll T; Andersen HU; Knop FK
BMJ Open; 2018 Jun; 8(6):e021861. PubMed ID: 29950475
[TBL] [Abstract][Full Text] [Related]
10. Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes.
Wilhelm-Benartzi CS; Miller SE; Bruggraber S; Picton D; Wilson M; Gatley K; Chhabra A; Marcovecchio ML; Hendriks AEJ; Morobé H; Chmura PJ; Bond S; Aschemeier-Fuchs B; Knip M; Tree T; Overbergh L; Pall J; Arnaud O; Haller MJ; Nitsche A; Schulte AM; Mathieu C; Mander A; Dunger D
BMJ Open; 2021 Dec; 11(12):e053669. PubMed ID: 34876434
[TBL] [Abstract][Full Text] [Related]
11. Type 1 diabetes in the Spanish population: additional factors to class II HLA-DR3 and -DR4.
Urcelay E; Santiago JL; de la Calle H; Martínez A; Méndez J; Ibarra JM; Maluenda C; Fernández-Arquero M; de la Concha EG
BMC Genomics; 2005 Apr; 6():56. PubMed ID: 15842729
[TBL] [Abstract][Full Text] [Related]
12. Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a Phase I/II randomised double-blind placebo-controlled trial.
Carlsson PO; Espes D; Sisay S; Davies LC; Smith CIE; Svahn MG
Diabetologia; 2023 Aug; 66(8):1431-1441. PubMed ID: 37221247
[TBL] [Abstract][Full Text] [Related]
13. Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)-study protocol for a phase 2, randomized, placebo controlled trial.
Waibel M; Thomas HE; Wentworth JM; Couper JJ; MacIsaac RJ; Cameron FJ; So M; Krishnamurthy B; Doyle MC; Kay TW
Trials; 2022 May; 23(1):433. PubMed ID: 35606820
[TBL] [Abstract][Full Text] [Related]
14. A quarter of patients with type 1 diabetes have co-existing non-islet autoimmunity: the findings of a UK population-based family study.
Kozhakhmetova A; Wyatt RC; Caygill C; Williams C; Long AE; Chandler K; Aitken RJ; Wenzlau JM; Davidson HW; Gillespie KM; Williams AJK
Clin Exp Immunol; 2018 Jun; 192(3):251-258. PubMed ID: 29431870
[TBL] [Abstract][Full Text] [Related]
15. Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial.
Gitelman SE; Gottlieb PA; Felner EI; Willi SM; Fisher LK; Moran A; Gottschalk M; Moore WV; Pinckney A; Keyes-Elstein L; Harris KM; Kanaparthi S; Phippard D; Ding L; Bluestone JA; Ehlers MR;
Diabetologia; 2016 Jun; 59(6):1153-61. PubMed ID: 27053235
[TBL] [Abstract][Full Text] [Related]
16. High-risk genotypes HLA-DR3-DQ2/DR3-DQ2 and DR3-DQ2/DR4-DQ8 in co-occurrence of type 1 diabetes and celiac disease.
Smigoc Schweiger D; Mendez A; Kunilo Jamnik S; Bratanic N; Bratina N; Battelino T; Brecelj J; Vidan-Jeras B
Autoimmunity; 2016 Jun; 49(4):240-7. PubMed ID: 27138053
[TBL] [Abstract][Full Text] [Related]
17. Assessing the efficacy, safety and utility of closed-loop insulin delivery compared with sensor-augmented pump therapy in very young children with type 1 diabetes (KidsAP02 study): an open-label, multicentre, multinational, randomised cross-over study protocol.
Fuchs J; Allen JM; Boughton CK; Wilinska ME; Thankamony A; de Beaufort C; Campbell F; Yong J; Froehlich-Reiterer E; Mader JK; Hofer SE; Kapellen TM; Rami-Merhar B; Tauschmann M; Hood K; Kimbell B; Lawton J; Roze S; Sibayan J; Cohen N; Hovorka R;
BMJ Open; 2021 Feb; 11(2):e042790. PubMed ID: 33579766
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor-associated susceptibility to type 1 diabetes is caused by linkage disequilibrium with HLA-DR3 haplotypes.
Kumar N; Kaur G; Tandon N; Mehra N
Hum Immunol; 2012 May; 73(5):566-73. PubMed ID: 22366579
[TBL] [Abstract][Full Text] [Related]
19. GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30 months.
Ludvigsson J; Chéramy M; Axelsson S; Pihl M; Akerman L; Casas R;
Diabetes Metab Res Rev; 2014 Jul; 30(5):405-14. PubMed ID: 24302596
[TBL] [Abstract][Full Text] [Related]
20. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials.
Schloot NC; Meierhoff G; Lengyel C; Vándorfi G; Takács J; Pánczél P; Barkai L; Madácsy L; Oroszlán T; Kovács P; Sütö G; Battelino T; Hosszufalusi N; Jermendy G
Diabetes Metab Res Rev; 2007 May; 23(4):276-85. PubMed ID: 17103487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
